Cutter & CO Brokerage Inc. Sells 36 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Cutter & CO Brokerage Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 721 shares of the medical research company’s stock after selling 36 shares during the quarter. Cutter & CO Brokerage Inc.’s holdings in Thermo Fisher Scientific were worth $383,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Raleigh Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares in the last quarter. Operose Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after acquiring an additional 75 shares in the last quarter. Financial Connections Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $53,000. Finally, Valley National Advisers Inc. grew its stake in shares of Thermo Fisher Scientific by 40.5% in the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after acquiring an additional 32 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $1.68 on Wednesday, reaching $576.27. The stock had a trading volume of 1,045,801 shares, compared to its average volume of 1,555,087. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a market cap of $219.97 billion, a P/E ratio of 37.22, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $572.03 and its two-hundred day moving average is $528.72.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the firm posted $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research analyst reports. Raymond James boosted their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. The Goldman Sachs Group boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Royal Bank of Canada boosted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, HSBC boosted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.